References:
1. L.C. Wienkers, R.C. Steenwyk, S.A. Miszak and P.G. Pearson. In Vitro Metabolism of Tirilazad Mesylate in Male and Female Rats: Contribution of P4502C11 and ?4-5a-reductase. Drug Metab. Dispos., 23, 383-392 (1995).
2. L.C. Wienkers, R.C. Steenwyk, P.E. Sanders and P.G. Pearson. Biotransformation of tirilazad in human : 1. Cytochrome P4503A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J. Pharmacol. Exp. Therap., 277, 982-990 (1996).
3. J.C. Fleishaker, P.G. Pearson, L.C. Wienkers, L.K. Pearson and G.R. Peters. Biotransformation of tirilazad in human : 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J. Pharmacol. Exp. Therap., 277, 991-998 (1996).
3. L.C. Wienkers, R.C. Steenwyk, M.J.Hauer, J.C. Fleishaker and P.G. Pearson. Biotransformation of tirilazad in human: 3. Tirilazad mesylate A-ring reduction by ?4-5a-reductase type-1 and type-2. J. Pharmacol. Exp. Therap., 287, 583-590(1998).
5. J.C. Fleishaker, P.G. Pearson, L.C. Wienkers, L.K. Pearson, T.A. Moore and G.R. Peters. Biotransformation of tirilazad in human: 4. Effect of finasteride on tirilazad clearance and reduced metabolite formation. J. Pharmacol. Exp. Therap., 287,591-507 (1998).
6. F.P. Abramson, Y. Teffera, J. Kusmierz, R.C. Steenwyk and P.G.Pearson. Replacing 14C with stable isotopes in drug metabolism studies. Drug Metab. Dispos. 24, 697-701 (1996).
This page has been accessed
times since 9/15 /96 .
Last Updated Tuesday, March 30, 1999 9:00:19 AM